• Mallinckrodt Completes Acquisition of Ocera Therapeutics, OCR-002 americanpharmaceuticalreview
    December 12, 2017
    Mallinckrodt has closed the acquisition of Ocera Therapeutics, a clinical-phase biopharmaceutical company focused on the development and commercialization of novel therapeutic drugs for orphans and other serious liver diseases that have not been met
  • Mallinckrodt to Acquire Ocera Therapeutics, OCR-002 americanpharmaceuticacreview
    November 03, 2017
PharmaSources Customer Service